BGMA response to Branded Medicines Consultation
Warwick Smith, Director General of the BGMA, has welcomed the DofH's decision not to introduce an additional price cut for branded generic medicines...
List view / Grid view
News
Astrazeneca, MD Anderson enter collaboration to help improve patient outcomes in ovarian / gynecologic cancers
30 January 2015 | By AstraZeneca and The University of Texas MD Anderson Cancer Center
AstraZeneca and The University of Texas MD Anderson Cancer Center announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes...
Ovarian Cancer treatment market in Asia-Pacific to undergo modest growth by 2020, says GBI Research
30 January 2015 | By GBI Research
The Asia-Pacific therapeutics market for Ovarian Cancer will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, at a Compound Annual Growth Rate of 5.1%, says business intelligence provider GBI Research...
Nabriva Therapeutics strengthens Board and Management Team
30 January 2015 | By Nabriva Therapeutics AG
Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board...
Expert panel recommends new approaches to management of autosomal dominant polycystic kidney disease (ADPKD)
30 January 2015 | By Virgo Health
European ADPKD Forum report expands current ADPKD evidence base...
electroCore’s non-invasive vagus nerve stimulation therapy (nVNS) confirmed as safe
30 January 2015 | By electroCore
Non-invasive vagus nerve stimulation (nVNS) ‘improves the safety and tolerability of VNS making it more accessible and facilitating further investigations across a wide range of uses when compared with surgically implanted VNS’ according to a review in the European Journal of Neurology...
Two thirds of Britons would have genetic test to identify risk of disease if it were free on the NHS
29 January 2015 | By The Astellas Innovation Debate
Two thirds (66%) of the population would want to know whether they had a risk of developing a serious illness, such as cancer, if genetic testing were available for free on the NHS...
AstraZeneca announces four collaborations to use CRISPR technology for genome editing across its drug discovery platform
29 January 2015 | By AstraZeneca
AstraZeneca has announced 4 research collaborations aimed at harnessing CRISPR, a pioneering genome-editing technique, across its entire discovery platform...
BMG LABTECH – the Microplate Reader Company – celebrates 25 successful years
28 January 2015 | By BMG LABTECH
Since its establishment in 1990, BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies...
Successful business year 2014: Sartorius achieves sales and earnings targets – positive outlook for 2015
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, successfully closed fiscal 2014 according to its preliminary figures, and even slightly exceeded its sales revenue and earnings targets. In addition, the Group is set to further sharpen its strategic profile based on the sale of its smallest division, Industrial Technologies,…
European Hantavirus diagnostics market tops US market as a result of higher disease prevalence
28 January 2015 | By Frost & Sullivan
Frost & Sullivan says existing competitors’ dominance of the niche market raises entry barriers...
Roche delivers solid results in 2014
28 January 2015 | By Roche
Pharmaceutical giant Roche delivers its 2014 year-end results...
Screen time, not face time
28 January 2015 | By The Astellas Innovation Debate
British patients happy to have webcam consultations – especially the over 55s...
Sparse pipeline for acromegaly and gigantism treatment limiting market growth, says GlobalData
28 January 2015 | By GlobalData
The acromegaly and gigantism treatment market will expand at a modest Compound Annual Growth Rate (CAGR) of 3.74% from approximately $588 million in 2013 to $707 million by 2018, limited by a sparse pipeline, according to research and consulting firm GlobalData...
Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio.
